Disclosure: I have written this as a promotional piece in conjunction with the 18th eyeforpharma Barcelona conference (Reuters Events), from a patient perspective as a patient advocate supporter of eyeforpharma. Included are varying links to their conference online brochure. No monies have been exchanged
Page 1 – Contents & Introduction
Including links to:
- ARTICLE: Pharma collaborations that need to happen in 2020 | Kris Sterkens
- VIDEO CLIP: Kris Sterkens #efpbarca 2019 ‘Eisenbahnscheinbewegung’
- ARTICLE: Breaking out of data silos in commercial | eyeforpharma | By Ulrich Neumann
- ARTICLE: What effect will purpose have on your reputation this year? Infographic download | Reputation Institute
- REPORT: 2020 Global Trends in Reputation | Reputation Institute
Page 2 – 18th Annual eyeforpharma Barcelona 2020 Conference
Including links to:
- Conference website eyeforpharma Barcelona 2020 · March 31 – April 2
- Full speaker list
- eyeforpharma ARTICLE: Has direct to consumer marketing in pharma had its day? | By Lucy Fulford on Nov 25, 2019
- eyeforpharma ARTICLE: Time to embrace social media | By Katie Osborne on Feb 4, 2020 | eyeforpharma
- eyeforpharma ARTICLE: Advancing RWE together with academia | By Katie Osborne on Jan 2, 2020
- Digitally transform medical affairs without compromising authenticity download the whitepaper here
- eyeforpharma ARTICLE: Scaling patient engagement for deeper insights and better outcomes | By Lucy Fulford on Jan 13, 2020 | eyeforpharma
- Exclusive Roundtable Summary download from eyeforpharma Patient Summit Oct 2019 What Patients Want
- eyeforpharma ARTICLE: Clinical must think outside, and inside the box | Paul Simms Nov 21, 2019
- Sign up for eyeforpharma’s on demand content
- Webinar: Deliver digital endpoints Find new outcomes fast, and fulfil the promise of technology
- Webinar: From Digital Health Solutions to DTx Start with why!
- eyeforpharma Whitepaper: ‘Navigate regulations and reimbursement to reach patients’
- Innovation agenda
- Conference Agenda Themes
Special discussion regarding patient Engagement and then ‘What is Patient Centricity Q & A with Paul Simms, Chairman at eyeforpharma
Including links to:
- ARTICLE: Five shifts toward consumer-centric transformation | By Jeff Gourdji on Oct 14, 2019 | eyeforpharma
- ARTICLE: Where next for patient centricity in pharma? | Paul Tunnah from Pharmaphorum
- ARTICLE: The importance of patient engagement | By Craig Bradley -January 28, 2019
- ARTICLE: Advancing patient engagement | Pharma Times October 2019
- ARTICLE: Making the most of patient engagement | By Barbara Lopez Kunz 22-Jan-2019
- ABOUT US: Patient Focused Medicines Development (PFMD)
- WEBSITE: European Patients Forum
- ARTICLE: Patient centricity: What is it – and why aren’t we there yet? | Zuzanna Fimińska 2014
- ARTICLE: Whose data is it anyway? | By Andy stone on Aug 30, 2019 | eyeforpharma
- ARTICLE: Making it about the patient, with the patient | Danielle Barron | eyeforpharma
- ARTICLE: RWE: A new hope for rare disease | By Lucy Fulford on Jan 30, 2020 | eyeforpharma
- Conference website: 18th annual eyeforpharma Philadelphia Conference
- WEBSITE: Read all about the Patient Engagement Open Forum
- ARTICLE: Into pharma’s roaring twenties | Paul Simms | Published on LinkedIn January 8, 2020
- ARTICLE: Patient Centricity: The Changing Paradigm For Pharma BY Dr Ammar Raza, ©
- ARTICLE: Walking the patient centric talk | Published in PharmaTimes magazine – May 2018 by Katrina Megget
- ARTICLE: Patient centricity efforts becoming more wide-ranging and sophisticated, say CROs | 11-Sep-2019 By Melissa Fassbender
- ARTICLE: A year of building patient centric foundations | By Amanda Barrell December 19, 2019 | pharmaphorum
- Conference website eyeforpharma Barcelona 2020 · March 31 – April 2
Since 2017 I have had a keen interest in this event for the way that it approaches the need for patients within the pharma landscape. Okay, I hear a few ‘cynics’ sighing and saying under their breath “it is easy to plonk a few patients on an agenda and say that you’re patient friendly isn’t it?” Well you’re right, it is easy to do that, but that is not how eyeforpharma operate and it is something that I can validate through personal experience.
With a ‘patient-centric landscape‘ finally beginning to look like it is developing not only in Europe, but across the Globe in many other areas, as well as pharma, it is fair to suggest that patients had something to do with that. I know that I can hold my hands up and say that I helped, well at least so people keep telling me anyways.
My views should be quite well-known by now about how patient healthcare as a whole should be operating due to the nature of the ‘patient landscape’ relying heavily on each, and every, stakeholder for their survival. Okay, I will say it again just in case there are new readers out there. In other words for our lives to go on we need ‘all-stakeholders’ so that we can live through the illnesses that we do every day. Whether it’s pharma, clinical, medical, digital, HCPs, diagnostics, research, and so on… Pharma, in our world is only part of the solution, but the changes and developments that I have witnessed since 2017 have been huge by pharma, even though they’re only little in reality with a lot of work still left to do.
Read what Kris Sterkens has to say about pharma, collaboration and multi stakeholders:
Pharma collaborations that need to happen in 2020 | Kris Sterkens Company Group Chairman – Janssen Europe, Middle East and Africa (EMEA) | LinkedIn Published on January 28, 2020
Last year, at the eyeforpharma Barcelona conference, I heard Kris present and talk about the concept of ‘Eisenbahnscheinbewegung’, and it was a quite a compelling presentation. In fact one that has resonated quite far since then within pharma.
Don’t be misconceived because taking the ‘all-stakeholder’ approach into consideration appears to have been accepted across many sectors of the medical healthcare industries and #notjustpharma!
It is partially because of this that it is ‘my opinion’ that patient centricity has been easier to navigate. Of course, we are obliged, if not ushered, in current day to call it ‘person-centricity’ just as much due to everyone being patients, patients being people first, and generally because patients are #notjustpatients, in fact often caregivers, workers, or volunteers like I am who spend time advocating, raising awareness, running support groups and supporting / advising the needs of those who are chronically ill.
Before I entered the world of pharma as an advocate I didn’t see myself as a patient, in fact I saw myself as a ‘person with multiple chronic illnesses, including rare diseases‘. I’ve spent a short while adjusting to being referred to as a patient, trying to get our members, etc, to also view themselves as patients only to now have to readjust back to how it was before. Patient centric ideals are all working towards placing patients at the centre regardless of what you call us, and it must also be remembered that everyone is a patient, you don’t have to be chronically ill!
When I began using the hashtag #notjustpatients it was because we’re not, but it was also a ‘double entendre‘ and this is something that I’ve explained before. FibroFlutters have always had an ‘all is welcome‘ policy and we turn 6 on May 12th. We were not influenced by pharma, or medical per se, in fact our decision as Founding members was based purely on our personal experiences as people and our needs in life living with chronic illness.
The irony of discovering the pharma ideal of patient centricity could be called ‘an omen‘, ‘coincidence‘, or just a plain simple ‘flow‘ of circumstance. It is a discovery that has changed my whole life, with the help from eyeforpharma, as it opened my eyes beyond the ‘patient‘ window to see that our ideals existed in other areas of the medical and healthcare industries. We were not fighting our fight alone!
However, on the other hand it would be unfair to ‘not’ discuss the fact that the whole ‘dance’ about patient centricity appears to have become subdued as the industry takes on board the whole change towards implementing digital and AI technologies.
I’m not suggesting that this change to the industry landscape isn’t required because in order for medicines development to become more economical, and personalised, ‘digitalisation’ is proving to be an essential component. The talk of virtual trials for instance to help with trial retention by connecting patients who live in far away locations, or are too sick to leave the house. The introduction of telehealth services would be extremely beneficial. Digital healthcare services are not currently viewed as marvelous by patients, but it is something we will have to learn to like. Our data isn’t safe, well at least that is the general consensus. However, everyone is happy that they don’t have to repeat their medical biography every time they see a healthcare professional.
It is time to move onwards and focus on sorting out those data silos, training everyone how to engage with digital health as I’m fairly certain that we are all on the way to sorting out how to build relationships and engage with one another. Yes, there’s still work to do, but my point is that we know how to do it now so let’s just get on with it so we can figure out solutions for another bottleneck that is blocking progress ie: data silos for example.
None of it, in my opinion is attainable without remembering to implement patient / person centric approaches, though, so they should still be portrayed at the forefront of company strategies. At this point I remind my readers that although I am not a ‘pharma’ executive or experienced in pharma, I do know about business strategy, supply chain strategy and corporate ‘social‘ responsibility, taking these business aspects to help design a more aesthetically pleasing company by means of building reputation. (It’s called corporate responsibility now, social was dropped and the term means responsibility to all)
Read this article
Breaking out of data silos in commercial | eyeforpharma | By Ulrich Neumann on Oct 21, 2019
Pharma’s commercial teams have much to gain if they can overcome technical and cultural blockages that prevent data sharing
On page 3 of this #efpbarca special there is a bonus Q & A with Paul Simms, Chairman of eyeforpharma when I asked him what he thinks ‘Patient Centricity‘ means today in 2020 compared to back in 2014
Okay, previously I mentioned CSR, Corporate Social Responsibility, which appears to be viewed as an ancient toolkit from 20+ years ago, but in my opinion it is useful in the modern day of 2020.
Something that businesses seem to be slow at understanding is that Corporate Responsibility is at the heart of reputation building, which has been proven to increase trust within stakeholder relationships. No business can survive without those relationships no matter who the stakeholder is. This to me is why all stakeholders should be included in company manifestos and supply chain strategies. Pharma supply chains, to me, are complicated so require an intense structure that can carry the weight of what they hold.
It is common sense to me that reducing all potential bottlenecks before implementing new supply chain strategies is a necessity so adhering to social responsibilities from the beginning is also common sense.
What effect will purpose have on your reputation this year?
Higher Purpose and Data Privacy Rise in Importance in 2020 Global Trends Report Download the Infographic…
Read the report – 2020 Global Trends in Reputation
I’m pleased to see that the agenda is addressing many areas, including elements of CSR, and I will have the opportunity to experience for myself how it works out. It appears that dealing with patients is the core responsibility that will be addressed. However, there are many other aspects that can help a company to boost its reputation. Building stakeholder relationships ‘per se’ of course, and not just with patients, is also being tackled, but it is time to consider other things, and new ideas would freshen up the changing landscape. With it being a new decade it is rather an appropriate time to make those changes.
What I want to hear is how companies are approaching the other social responsibilities and will be listening closely to find out. Just because I’m a patient doesn’t mean that I am only interested in the ‘Patient Track!
Yes, I have a complimentary patient pass, my flights and accommodation are booked and I can’t keep my eyes of the ever developing agenda.
At this point I’d like say a big thank you to eyeforpharma (Reuters events) and Paul Simms for that patient pass
So, why do I write all this in accordance to the 18th eyeforpharma Barcelona Conference 2020?
That is an easy question to answer considering what is on their agenda and the fact that I believe you all need reminding about what is the strong centerfold behind it. What is the key driver that helped to produce the progressional changes to begin with… which was that urge and desire for patient centricity!